Citation: Roessling G, “The Universe of Pre-Filled Syringes & Injection Devices”. ONdrugDelivery Magazine, Issue 79 (Oct 2017), pp 62-63.

The new business reality for prefilled syringes centres around self-injection delivery systems adapted to the needs of individual patients, a fact which will certainly have a clear and decisive impact on the pharmaceutical market. At the same time, these new products will require new approaches to addressing the needs of regulators.

The US FDA has in recent years expressed concerns about errors related to self-administration by patients, necessitating more attention to human factors analysis during the development cycle.1 Lifecycle management during manufacturing will also be critical to the success of self-administered injection devices. But how can manufacturers of prefilled devices learn more about the latest developments in this area as well as gain a sense for the larger business environment and regulatory picture?

This year’s Universe of Pre-filled Syringes and Injection Devices will examine these increasingly important issues. In the opening keynote presentation, Pfizer’s Simon Wilson and Amgen’s Sheldon Moberg will look at the issues of evolving perspectives on connectivity and patient-centric solutions respectively. The talks in this session will cover outcomes-based adaptive reimbursement. Such arrangements between payers and pharma have been made for multiple self-injected drugs. The subsequent drug delivery implications will also be discussed. Following up on this, there will be a review on the payer’s view of value of drug delivery devices on the second day. Results of conversations with payer executives will be presented on how to improve population health with the assistance of drug delivery technology.

The conference will be distributed in three tracks, each one addressing a highly in-demand topic of discussion. One track will address marketing and business development for prefilled syringes. The first session in this track will cover lifecycle management, featuring a case study on how an off-patent IV drug was filed in a SC version using a patch pump. A second case study from Japan will describe the impact of a third-generation digital auto-injector for a growth hormone franchise. The second day of the track will start with a session on market trends and reimbursement. Delegates will receive an update on the latest overall market trends followed by presentations on reimbursement. The final presentation of the session will review the evolving payer perspective on the value of drug delivery devices. The last session will focus on business strategies.

The conference will also feature an exhibition, with more than 100 exhibitors in a 7,500 m2 hall, and an extensive education programme with focused training courses.

The Universe of Pre-filled Syringes and Injection Devices takes place on November 7-8, 2017, at the Vienna Center, Vienna, Austria. For more information visit the event web page, and don’t forget to download the Event App, available for Android and Apple devices.

PDA looks forward to welcoming you in Vienna next month!


  1. Baker J, “Educating patients on self-administered drug injections”. Pharmaceutical Online, January 20, 2014. (